PharmaShots Weekly Snapshots ( October 30

This week PharmaShots’ news was all about the updates on clinical trials, regulatory, pharma, M&A, MedTech, and DigiHealth. Check out our full report below:

The US FDA Approved Merck’s Keytruda with Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer

Read More:- Merck

Coherus and Junshi Bioscience's Loqtorzi (toripalimab-tpzi) Received the US FDA’s Approval to Treat Nasopharyngeal Carcinoma (NPC)

Read More:- Coherus and Junshi Bioscience

The US FDA Grants Santhera’s Agamree (vamorolone) Approval for the Treatment of Duchenne Muscular Dystrophy (DMD)

Read More:- More Santhera

Idorsia Pharmaceuticals Reports the NDA Submission of Daridorexant to the PMDA for the Treatment of Insomnia

Read More:- Idorsia Pharmaceuticals

BMS Receives EMA’s Validation of Opdivo (nivolumab) + Cisplatin-Based CT for 1L Treatment of Unresectable or Metastatic Urothelial Carcinoma

Read More:- BMS

Novartis Received The US FDA's Approval for Cosentyx to Treat Hidradenitis Suppurativa

Read More:- Novartis

The US FDA Approved Amgen's Wezlana (Biosimilar, ustekinumab) for the Treatment of Multiple Inflammatory Diseases

Read More:- Amgen

Abbott's Alinity M High Risk (HR) HPV assay for the Detection of HPV Infections has been approved by the US FDA

Read More:- Abbott

The US FDA has accepted to review the resubmitted NDA of Supernus' SPN-830 for the Treatment of Off Episodes in Parkinson’s Disease

Read More:- Supernus

GSK Reports Positive Results of P-III Study (RUBY) for Jemperli + CT in Primary Advanced or Recurrent Endometrial Cancer Patients

Read More:- GSK

Novartis’ Reports Results of Atrsentan in P-III Study for the Treatment of IgA Nephropathy

Read More:- Novartis

Otsuka Pharmaceutical Reports Results for Centanafadine in Two P-III Trials for the Treatment of ADHD

Read More:- Otsuka Pharmaceutical

Teva Pharmaceutical Reports P-III Results of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia

Read More:- Teva Pharmaceutical

T3D Therapeutics has announced promising outcomes from the P-II study (PIONEER) of T3D-959 in the treatment of Alzheimer's Disease

Read More:- T3D Therapeutics

Innate Pharma Presents P-II Study (TELLOMAK) Results of Lacutamab for the Treatment of Sézary Syndrome

Read More:- Innate Pharma

Roche Reports Positive Efficacy Results from the P-III Study (EMBARK) of Elevidys for Duchenne Muscular Dystrophy (DMD)

Read More:- Roche

Merck Reports Secondary Endpoint Results of Keytruda in P-III Trial for the Treatment of Renal Cell Carcinoma (RCC)

Read More:- Merck

Adaptimmune Reports Positive Data from the P-II Trial Assessing Lete-cel for the Treatment of Synovial Sarcoma And Myxoid/Round Cell Liposarcoma (MRCLS)

Read More:- Adaptimmune

UCB Publishes the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy in ‘Epilepsy & Behavior’

Read More:- UCB

Henlius Brings Hansizhuang (serplulimab injection) to Europe and India Through an Exclusive Licensing Agreement with Accord Healthcare

Read More:- Henlius & Accord Healthcare

Sosei Heptares Receives a Milestone Payment of $3.75M as a Part of its Multi-Target Agreement with Genentech

Read More:- Sosei Heptares & Genentech

Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement for the Development of HRS-1167 and SHR-A1904 to Treat Cancer

Read More:- Merck KGaA and Hengrui Pharma

Zydus and Guardant Health will Co-Promote the Guardant360 portfolio which includes Guardant360 and Guardant360 TissueNext tests for advanced solid cancers in India and Nepal

Read More:- Zydus and Guardant Health

AstraZeneca Signs a Collaboration Agreement with Cellectis to Develop Novel Cell and Gene Therapies for Oncology and Immunology Indications

Read More:- AstraZeneca & Cellectis

Abcellera and Prelude Therapeutics Entered into a Partnership to Develop ADCs Therapies for the Treatment of Cancer

Read More:- Abcellera and Prelude Therapeutics

Aldeyra Therapeutics Signs an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease

Read More:- Aldeyra Therapeutics & AbbVie

GSK Enters into an Agreement with Janssen and Arrowhead for JNJ-3989 to Treat Chronic Hepatitis B

Read More:- GSK, Janssen and Arrowhead